Medicenna Therapeutics Corp T.MDNA

I like this .

[Galaxym31]

The global multi-arm Phase 1/2 ABILITY-1 study is expanding to various cancer centers in the US, Canada, Australia, South Korea and Europe evaluating MDNA11 as a single-agent and in combination with KEYTRUDA® in patients with advanced solid tumors. For bizaxofusp, we plan to seek Breakthrough Therapy

[ENEMENEMYNEMO]

Keytruda 30 billion/yr sales.  Patent expires 2028. Merck needs a reformulation.  Addition of MDMA-11 (if trial shows success) as a combination  drug would give Merck an extra 20 years on the Patent. If this plays out the potential profits for both companies here would be astronomical!